Epinephrine (DB00668): A Comprehensive Monograph on its History, Pharmacology, and Clinical Utility

Introduction

Epinephrine, known also by its British Approved Name, Adrenaline, stands as a paramount molecule in both human physiology and clinical medicine. It is an endogenous catecholamine that functions dually as a hormone, synthesized and released by the chromaffin cells of the adrenal medulla, and as a neurotransmitter within select pathways of the central nervous system.[1] This dual role places it at the center of the body's acute stress response, orchestrating the profound physiological shifts colloquially known as the "fight-or-flight" response.[2] The discovery and isolation of this potent substance over a century ago marked a watershed moment in science, effectively launching the field of endocrinology and providing medicine with one of its most powerful and versatile tools.

The therapeutic utility of epinephrine is a direct translation of its physiological functions. It is the cornerstone of emergency treatment for life-threatening conditions, most notably Type I hypersensitivity reactions, including anaphylaxis, where its multifaceted actions are uniquely suited to counteract systemic collapse.[4] Its potent cardiovascular effects are harnessed in the management of cardiac arrest and as a vasopressor agent to combat profound hypotension in septic shock.[2] Furthermore, its applications extend to the emergency management of severe asthma, as an essential adjunct to local anesthetics, and in ophthalmic procedures to control intraocular pressure and induce mydriasis.[4]

The pharmacological basis for this broad utility lies in its action as a potent, non-selective agonist of both α- and β-adrenergic receptors.[4] The balance of these receptor effects is exquisitely dose-dependent, allowing clinicians to elicit different primary responses—from cardiac stimulation at low doses to powerful vasoconstriction at high doses—by carefully titrating its administration.[4] However, this same potency necessitates a profound respect for its potential adverse effects, which are predictable extensions of its mechanism and require vigilant monitoring.

This report aims to provide an exhaustive, multi-faceted analysis of epinephrine (DrugBank ID: DB00668; CAS Number: 51-43-4). By synthesizing its rich historical context, detailed physicochemical and pharmacological properties, comprehensive clinical applications, and robust safety profile, this document serves as a definitive monograph for medical professionals, pharmacologists, and researchers.

Section 1: A Historical Chronicle of a Landmark Discovery

The story of epinephrine is inextricably linked to the birth of modern endocrinology and pharmacology. Its journey from an unknown substance within an enigmatic gland to a purified, life-saving medication is a testament to the progression of scientific inquiry over the last 150 years.

The Pre-Discovery Era: An Enigmatic Gland

For centuries, the adrenal glands were an anatomical curiosity. First described in 1564 by the Italian anatomist Bartolomeo Eustachio, their function remained a complete mystery.[9] A pivotal, albeit indirect, insight came in 1855 from the English physician Thomas Addison. In his monograph, "On the Constitutional and Local Effects of Disease of the Suprarenal Capsules," he described a fatal wasting syndrome—now known as Addison's disease—resulting from the destruction of these glands, thereby establishing for the first time that they were indispensable for life.[9] A year later, in 1856, Alfred Vulpian observed that ferric chloride stained the inner portion (medulla) of the gland green, suggesting it contained a unique chemical substance that was released into the bloodstream.[9]

The Dawn of Endocrinology (Late 19th Century)

The definitive step toward understanding the gland's function came in the 1890s. In a series of seminal experiments conducted between 1894 and 1895, the English physician George Oliver and his collaborator, the physiologist E. A. Schäfer, demonstrated that an extract of the adrenal medulla had a profound physiological effect when injected into animals. They observed a dramatic and rapid increase in heart rate and blood pressure, along with a slowing of respiration.[10] These experiments provided the first direct evidence of a powerful, chemically-mediated signal originating from a gland—a hormone—and ignited an intense international race to isolate this active principle.[9]

The Race for Isolation and Purification

The late 1890s saw several prominent scientists attempt to purify the pressor agent. John Jacob Abel, a distinguished pharmacologist at Johns Hopkins University, announced in 1899 that he had isolated the active compound, which he named "epinephrin".[10] However, his methods were complex, and his final product was later shown to be a relatively inactive benzoylated derivative of the true hormone.[9]

The breakthrough came from an industrial chemist, Jokichi Takamine, and his young assistant, Keizo Uenaka. Working in New York, Takamine and Uenaka developed a simple yet elegant method for purifying the substance from bovine adrenal glands. On August 5, 1900, they succeeded in producing a stable, pure crystalline product, which they named "adrenalin" on November 7, 1900.[9] Takamine's success was monumental; for the first time, a pure hormone was available in a stable, standardized form. This enabled reproducible physiological experiments and, crucially, the development of a reliable therapeutic agent. Parke-Davis & Company quickly recognized the commercial potential, patenting the product in 1903 and marketing it worldwide as "Adrenalin" in 1 mL ampules of a 1:1,000 solution.[9]

This progression from crude organ extracts to a single, purified, and mass-produced chemical compound represents a microcosm of the evolution of pharmaceutical science itself. It marked the transition from the imprecise world of organotherapy to the dawn of modern, molecule-based pharmacology, where the interplay of academic research, industrial chemistry, and commercial enterprise became the engine of medical innovation.

Structural Elucidation and the Enduring Nomenclature Debate

With a pure sample available, the chemical structure was soon determined. In 1901, T.B. Aldrich, working for Parke-Davis, correctly identified the empirical formula as C9​H13​NO3​.[6] The success of Takamine and Parke-Davis led to a lasting transatlantic debate over the drug's proper name. In the United States, the scientific establishment, influenced by Abel, championed the name "epinephrine," which was adopted by the U.S. Pharmacopeia. In Britain, physiologist Henry Dale argued for "adrenaline," and this name was adopted in the U.K. and much of the rest of the world.[9] This dual nomenclature persists today and reflects the early tensions between academic science and commercialized, patent-driven research that continue to shape the pharmaceutical landscape.

Early Clinical Adoption and Guideline Evolution

The availability of a standardized "Adrenalin" solution led to its rapid adoption in clinical practice. As early as 1901, it was used to treat hay fever, and by 1903, it was being used for asthma.[10] Early dosing was often imprecise, based on apothecary units like "minims" (approximately 0.06 mL) and guided by individual physician observation rather than rigorous trials.[10] Over the subsequent decades, its use expanded to include the treatment of anaphylactic shock and as a cardiac stimulant.[10]

The history of epinephrine's clinical use highlights a critical point: many of its most established applications were founded on a solid understanding of its physiological effects but were initially supported by empirical evidence and case reports, not the large-scale randomized controlled trials (RCTs) that are the gold standard today. For example, the standard 1 mg dose for cardiac arrest was not derived from dose-finding studies but was extrapolated from surgeons' observations of intracardiac injections in the operating room.[13] This historical context is vital for understanding why some long-standing practices are now being re-evaluated through the lens of modern, evidence-based medicine, as seen in the ongoing debate about the drug's impact on neurological outcomes after cardiac arrest.[14]

Section 2: Physicochemical Profile and Synthesis

A comprehensive understanding of epinephrine's actions begins with its fundamental chemical and physical properties, as well as the methods by which it is produced, both biologically and synthetically.

2.1 Chemical Identity and Stereochemistry

Epinephrine is a small molecule catecholamine. Its identity is standardized globally through various chemical and drug information systems.

• Identifiers: The compound is uniquely identified by its DrugBank Accession Number DB00668 and its Chemical Abstracts Service (CAS) Registry Number 51-43-4.[6] The CAS number specifically refers to the naturally occurring, biologically active isomer.
• Formula and Molecular Properties: The definitive chemical formula for epinephrine is C9​H13​NO3​.[6] It has a molar mass of approximately 183.2 g/mol (or 183.20 Da).[1] In its pure form, it appears as a white, microcrystalline solid or granule.[1]
• Nomenclature: The molecule is known by a variety of names. The official International Nonproprietary Name (INN) is Epinephrine, while the British Approved Name (BAN) is Adrenaline.[19] Its systematic IUPAC name is 4-benzene-1,2-diol.[12] It is marketed under numerous brand names, with the most recognizable being EpiPen, Adrenalin, Auvi-Q, and neffy.[6] A vast number of synonyms and historical names also exist, including L-Adrenaline, Suprarenin, and Levophed.[19]
• Stereochemistry: A critical feature of epinephrine's structure is the presence of a chiral center at the carbon atom bearing the hydroxyl group on the ethylamine side chain. This gives rise to two stereoisomers (enantiomers). The endogenous hormone and the active pharmaceutical ingredient is exclusively the (R)-(-)-enantiomer, also referred to as levo-epinephrine or L-epinephrine.[12] Its mirror image, the (S)-(+)-enantiomer (dextro-epinephrine), is substantially less biologically active.[20] Racemic mixtures, known as racepinephrine, contain both isomers and are consequently less potent than the pure (R)-(-)-form.[20] This stereospecificity is a classic example of a fundamental pharmacological principle: biological systems, being chiral themselves, interact with exquisite specificity with different stereoisomers of a drug. The superior biological activity of the (R)-(-) isomer is a direct result of its precise three-dimensional fit into the chiral binding pocket of adrenergic receptors, much like a right hand fits best into a right-handed glove. This structural requirement dictates that any viable chemical synthesis must include a step to isolate this specific, potent isomer.

Table 1: Physicochemical and Identification Data for Epinephrine

Parameter	Value	Source(s)
DrugBank ID	DB00668	6
CAS Number	51-43-4 ((R)-(-)-isomer)	12
Chemical Formula	C9​H13​NO3​	6
Molar Mass	183.20 g/mol	1
IUPAC Name	4-benzene-1,2-diol	12
Common Synonyms	Adrenaline, L-Epinephrine, (-)-Epinephrine	16
Active Isomer	(R)-(-)	12
Key Brand Names	EpiPen, Adrenalin, Auvi-Q, neffy, Primatene Mist	6
PubChem Identifier	5816	17

2.2 Biosynthesis and Chemical Synthesis

Epinephrine is available for therapeutic use through its isolation from natural sources (historically) and, more commonly today, through chemical synthesis.

• Endogenous Biosynthesis: In the body, epinephrine is synthesized primarily within the chromaffin cells of the adrenal medulla.[3] The biosynthetic pathway begins with the amino acid tyrosine, which is converted through a series of enzymatic steps to dopamine and then to norepinephrine. The final, defining step is the conversion of norepinephrine to epinephrine, a reaction catalyzed by the enzyme phenylethanolamine N-methyltransferase (PNMT).[3] The expression of PNMT is a key feature that distinguishes the adrenal medulla, allowing it to be the primary site of epinephrine production. Recent and compelling research has revealed that this pathway is not exclusive to the adrenal gland. The key enzyme PNMT is also expressed in other cell types, including pathogenic TH17 cells, a subset of T-lymphocytes involved in autoimmune diseases.[22] This finding has profound implications, suggesting that epinephrine can be produced locally within sites of inflammation. This local production may establish a paracrine signaling loop where inflammatory conditions trigger TH17 cells to synthesize epinephrine, which could then act on nearby blood vessels or other immune cells, potentially modulating the immune response or affecting tissue barriers like the blood-brain barrier. This opens an entirely new frontier of epinephrine research, investigating its role as a local immunomodulator far beyond its classical function as a systemic stress hormone.
• Pharmaceutical Chemical Synthesis: The industrial production of epinephrine for pharmaceutical use is a multi-step chemical process.[23] A common synthetic route starts with a catechol derivative, ω-chloro-3,4-dihydroxyacetophenone. This precursor is reacted with an excess of methylamine to form an intermediate ketone, ω-methylamino-3,4-dihydroxyacetophenone.[23] This ketone is then reduced to form the alcohol, yielding a racemic mixture of D,L-epinephrine. The reduction can be accomplished using various methods, including catalytic hydrogenation (e.g., over a Palladium on Carbon or Raney Nickel catalyst) or chemical reducing agents (e.g., sodium borohydride).[23] Because only the L(-)-isomer, which corresponds to the (R)-enantiomer, is therapeutically potent, the final and most critical step is the resolution of this racemic mixture. This is typically achieved by reacting the mixture with a chiral resolving agent, such as (+)-tartaric acid, which forms diastereomeric salts that have different solubilities and can be separated by crystallization, allowing for the isolation of the pure, active L(-)-epinephrine.[23]

Section 3: Pharmacodynamics: The Molecular Basis of Action

The diverse and powerful physiological effects of epinephrine are mediated through its interactions with a family of cell surface receptors known as adrenergic receptors (or adrenoceptors). Its clinical versatility and its side-effect profile are direct consequences of its complex, dose-dependent actions on these receptors.

3.1 Adrenergic Receptor Pharmacology

Epinephrine is a non-selective sympathomimetic catecholamine, meaning it mimics the effects of sympathetic nervous system stimulation by binding to and activating both major classes of adrenergic receptors: α-receptors and β-receptors.[4] These receptors are all members of the G-protein-coupled receptor (GPCR) superfamily, which transduce extracellular signals into intracellular responses via second messenger systems.[4]

• α-Adrenergic Receptor Effects:
• α1 Receptors: These receptors are primarily located on the smooth muscle of blood vessels (arterioles) in the skin, mucosa, splanchnic circulation, and kidneys, as well as on the pupillary dilator muscle of the iris.[4] Upon activation by epinephrine, α1 receptors couple to Gq proteins. This activates the enzyme phospholipase C, which generates inositol trisphosphate ( IP3​) and diacylglycerol (DAG). IP3​ triggers the release of calcium (Ca2+) from intracellular stores, leading to smooth muscle contraction.[3] The physiological result is potent vasoconstriction, which increases systemic vascular resistance and elevates blood pressure. This is the principal mechanism behind epinephrine's use as a vasopressor in shock and as a hemostatic agent.[24] In the eye, this contraction leads to mydriasis (pupil dilation).[4]
• α2 Receptors: These receptors are found on presynaptic nerve terminals, pancreatic β-cells, and platelets.[3] They are coupled to Gi proteins, which inhibit the enzyme adenylyl cyclase, leading to a decrease in intracellular cyclic adenosine monophosphate (cAMP) levels.[3] On presynaptic neurons, this creates a negative feedback loop that inhibits the further release of norepinephrine. In the pancreas, α2 activation inhibits insulin secretion.[3]
• β-Adrenergic Receptor Effects:
• β1 Receptors: These receptors are predominantly located on the heart, specifically in the sinoatrial (SA) node, atrioventricular (AV) node, and on cardiac myocytes, as well as in the kidneys.[4] They are coupled to Gs proteins, which stimulate adenylyl cyclase, increasing intracellular cAMP levels and activating protein kinase A (PKA).[3] In the heart, this signaling cascade produces powerful positive effects:
• Chronotropic: Increased heart rate (tachycardia).
• Inotropic: Increased force of myocardial contractility.
• Dromotropic: Increased speed of electrical conduction through the AV node.
• Lusitropic: Increased rate of myocardial relaxation. Collectively, these actions dramatically increase cardiac output.4 In the kidneys, β1 activation stimulates the release of renin, activating the renin-angiotensin-aldosterone system.4
• β2 Receptors: These receptors are widely distributed on smooth muscle in various organs, including the bronchioles of the lungs, blood vessels supplying skeletal muscle, the uterus, and the gastrointestinal tract.[7] Like β1 receptors, they are coupled to Gs proteins and increase cAMP. However, in smooth muscle, this increase in cAMP leads to relaxation.[25] The key physiological effects are potent bronchodilation (relieving airway obstruction), vasodilation in skeletal muscle beds (shunting blood to muscles during the fight-or-flight response), and relaxation of uterine (tocolysis) and GI smooth muscle.[4] β2 activation also stimulates hepatic glycogenolysis and gluconeogenesis, leading to an increase in blood glucose levels.[7]

3.2 Dose-Response Relationship and Systemic Effects

The single most important concept governing the clinical use of epinephrine is its dose-dependent pharmacology. The overall physiological effect is determined by the balance of α- and β-receptor stimulation, which changes dramatically with the concentration of the drug at the receptor sites. Functionally, epinephrine behaves as two different drugs depending on the dose administered.

• Low Doses: At low concentrations, such as those achieved with a slow intravenous infusion (e.g., 1-2 mcg/min), epinephrine exhibits a higher affinity for β-receptors.[4] The dominant effects are therefore β1-mediated increases in heart rate and contractility, leading to increased cardiac output, and β2-mediated vasodilation in skeletal muscle beds. This vasodilation can lower or maintain peripheral resistance, often resulting in a widened pulse pressure (increased systolic pressure with a decreased diastolic pressure).[4] This profile makes low-dose epinephrine useful as a cardiac inotrope and chronotrope.
• High Doses: At higher concentrations, such as those achieved with a rapid intravenous bolus (e.g., 1 mg in cardiac arrest), the drug fully engages and saturates α1-receptors.[4] The resulting powerful α1-mediated vasoconstriction becomes the overwhelming effect, dramatically increasing systemic vascular resistance and causing a sharp rise in both systolic and diastolic blood pressure.[4] This intense pressor effect is essential for restoring perfusion to the heart and brain during cardiopulmonary resuscitation.

This dose-dependent duality is the key to understanding why the same molecule can be used for such disparate conditions as anaphylaxis (requiring a mix of α and β effects), septic shock (primarily α effects for pressor support), and symptomatic bradycardia (primarily β effects for cardiac stimulation). Misunderstanding this principle can lead to serious medication errors, such as administering a high-dose bolus when a low-dose infusion is indicated.

Furthermore, the classical understanding of epinephrine's action in the airways as a pure bronchodilator is being challenged by new findings. Research has shown that human airway smooth muscle cells express α1-receptors.[27] Under conditions of β2-receptor desensitization or tachyphylaxis—a state that can be induced by chronic overuse of standard asthma inhalers—epinephrine's effects can "switch." The blunted β2-mediated relaxation allows the underlying α1-mediated pro-contractile signal to become dominant, potentially leading to paradoxical bronchoconstriction.[27] This novel mechanism could provide a molecular explanation for why some patients with severe asthma become insensitive to β-agonists and may even experience worsening symptoms upon exposure to stress-induced epinephrine. This challenges classical teaching and suggests that targeting α1-receptors could be a future therapeutic strategy for severe, refractory asthma.

Table 2: Summary of Epinephrine's Actions on Adrenergic Receptor Subtypes

Receptor Subtype	Primary Locations	G-Protein Coupling	Key Physiological Effects	Clinical Relevance (Therapeutic & Adverse)	Source(s)
α1	Vascular smooth muscle (skin, viscera), Pupillary dilator muscle, Intestinal sphincters	Gq	Vasoconstriction, Mydriasis, Sphincter contraction	Therapeutic: ↑ Blood pressure (shock), Hemostasis (local anesthetic adjunct), Mydriasis (ocular surgery). Adverse: Severe hypertension, Ischemia (digits, skin), Decreased renal perfusion.	3
α2	Presynaptic nerve terminals, Pancreatic β-cells, Platelets	Gi	↓ Norepinephrine release, ↓ Insulin secretion, Platelet aggregation	Adverse: Hyperglycemia (inhibition of insulin), Potential for impaired tissue perfusion.	3
β1	Heart (SA node, AV node, myocytes), Kidneys	Gs	↑ Heart rate (chronotropy), ↑ Contractility (inotropy), ↑ Conduction velocity (dromotropy), ↑ Renin release	Therapeutic: ↑ Cardiac output (cardiac arrest, shock). Adverse: Tachycardia, Arrhythmias, Angina, Increased myocardial oxygen demand.	4
β2	Bronchial smooth muscle, Uterine smooth muscle, Vascular smooth muscle (skeletal muscle), Liver	Gs	Bronchodilation, Uterine relaxation (tocolysis), Vasodilation, Glycogenolysis	Therapeutic: Bronchodilation (anaphylaxis, asthma). Adverse: Tremor, Hyperglycemia, Hypokalemia.	7

Section 4: Pharmacokinetics: The Journey Through the Body

The clinical utility of epinephrine is defined not only by its potent effects but also by how the body handles it—its absorption, distribution, metabolism, and excretion (ADME). The pharmacokinetic profile of epinephrine is perfectly suited for its role as an endogenous mediator of acute stress and as an emergency therapeutic agent, characterized by rapid action and swift elimination.

4.1 Absorption (A)

The absorption of epinephrine is entirely dependent on the route of administration, as it has negligible bioavailability when taken orally due to extensive first-pass metabolism in the gastrointestinal tract and liver.[1] Therefore, it must be administered parenterally or via other non-oral routes for systemic effects.

• Intravenous (IV) Administration: This route provides immediate and 100% bioavailability, with an almost instantaneous onset of action.[4] It is the preferred route in critical care settings for continuous infusions in septic shock or for rapid bolus administration during cardiac arrest, where precise and immediate control over drug levels is paramount.[28]
• Intramuscular (IM) Administration: IM injection into the anterolateral aspect of the thigh (vastus lateralis muscle) is the gold-standard route for the emergency treatment of anaphylaxis.[30] The rich vascularity of this large muscle ensures rapid absorption into the systemic circulation, with an onset of action typically within 5 to 10 minutes.[28] The thigh is preferred over other sites like the deltoid or gluteal muscles, as absorption from the thigh is faster and more reliable.[28] However, in patients with severe hypotension or shock, poor muscle perfusion can delay absorption, a critical consideration in managing anaphylactic shock.[28]
• Subcutaneous (SC) Administration: SC injection results in slower and more variable absorption compared to the IM route due to the lower vascularity of subcutaneous fat.[28] This can unacceptably delay the onset of action in a life-threatening emergency like anaphylaxis, which is why the IM route is strongly preferred.[7]
• Intraosseous (IO) Administration: When IV access cannot be rapidly established during a resuscitation effort, the IO route serves as an effective alternative.[29] It involves injecting the drug directly into the bone marrow, which provides rapid access to the non-collapsible venous plexus within the bone, allowing entry into the central circulation at a rate comparable to IV administration.[31]
• Endotracheal (ET) Administration: In the rare event that both IV and IO access are unavailable, epinephrine can be administered via an endotracheal tube.[29] However, drug absorption from the lungs is erratic and unpredictable, and significantly higher doses (2 to 2.5 times the IV dose) are required to achieve a therapeutic effect. This route is considered a last resort.[29]
• Novel Routes of Administration: Recognizing that needle phobia and hesitation to perform an injection are major barriers to the timely use of epinephrine auto-injectors in the community, significant research is focused on developing non-invasive delivery systems.[35] Intranasal sprays (e.g., neffy) and sublingual formulations are being investigated in clinical trials.[25] Studies have shown that these routes can achieve plasma concentrations comparable to IM injection, offering a potentially less intimidating alternative that could improve real-world compliance and outcomes.[35] This represents a crucial shift in pharmaceutical development, where human factors engineering is prioritized alongside pure pharmacology to address a critical public health need.

4.2 Distribution (D)

Once absorbed into the bloodstream, epinephrine is distributed rapidly and widely throughout the body.[4]

• Volume of Distribution: It is rapidly taken up by well-perfused organs, particularly the heart, liver, kidneys, and skeletal muscle.[4] As a hydrophilic molecule, it does not readily cross lipid membranes, most notably the blood-brain barrier.[28] This property confines its major actions to the periphery, with central nervous system effects being largely indirect or limited.[26]
• Plasma Half-Life: The most defining pharmacokinetic characteristic of epinephrine is its extremely short plasma half-life, which is typically between 2 and 5 minutes.[1] This rapid clearance from the circulation means that for a sustained effect, as required in septic shock, a continuous intravenous infusion is necessary. For acute events like cardiac arrest or anaphylaxis, its short duration necessitates repeated doses if symptoms persist or recur.[4] This "fast on, fast off" profile is an evolutionary adaptation for an endogenous stress hormone, a feature that medicine has expertly leveraged for emergency therapeutics. It allows for a powerful, life-saving intervention that does not result in prolonged, dangerous overstimulation.

4.3 Metabolism (M)

Epinephrine is subject to extensive and rapid biotransformation, which is the primary mechanism for its termination of action.

• Metabolic Sites and Enzymes: The metabolism occurs predominantly in the liver, kidneys, and other extraneuronal tissues.[4] Two key enzymes are responsible for its degradation:

1. Catechol-O-methyltransferase (COMT): This enzyme methylates the catechol hydroxyl group.
2. Monoamine Oxidase (MAO): This enzyme oxidatively deaminates the amine side chain. These enzymes act sequentially to break down epinephrine into inactive metabolites.4

• Pharmacogenomics: The efficiency of epinephrine metabolism can vary between individuals due to genetic polymorphisms in the genes encoding these enzymes. For example, common variants in the COMT gene can result in high- or low-activity forms of the enzyme. Individuals with low-activity COMT may metabolize epinephrine more slowly, potentially leading to a more pronounced or prolonged response to the drug.[28] Similarly, variations in MAO gene expression can influence breakdown rates. This genetic variability underscores the importance of titrating epinephrine to clinical effect.

4.4 Excretion (E)

The final step in the elimination of epinephrine from the body is the excretion of its metabolites.

• Renal Excretion: The inactive metabolites, with the most prominent being metanephrine and vanillylmandelic acid (VMA), are eliminated from the body via the kidneys into the urine.[1] Measurement of VMA in a 24-hour urine collection is a common diagnostic test for conditions involving excess catecholamine production, such as pheochromocytoma.
• Unchanged Drug: Due to the high efficiency of its metabolic clearance, only a negligible fraction of an administered dose of epinephrine is excreted unchanged in the urine.[4]

Section 5: A Review of Clinical Applications

The clinical use of epinephrine is a masterclass in applied pharmacology. Each indication leverages one or more of its specific receptor-mediated effects to precisely counteract a distinct pathophysiological state. It is not a disease-modifying agent but rather a powerful, fast-acting physiology-correcting drug for acute, life-threatening emergencies.

5.1 First-Line Treatment for Anaphylaxis

Epinephrine is the absolute, undisputed cornerstone of treatment for anaphylaxis, a severe, life-threatening systemic allergic reaction.[4] It is the only single medication that can simultaneously address the multiple catastrophic events of anaphylaxis. The pathophysiology of anaphylaxis involves massive, systemic release of histamine and other mediators from mast cells and basophils, leading to vasodilation, increased vascular permeability, bronchoconstriction, and laryngeal edema.[25] Epinephrine's comprehensive mechanism directly opposes these effects:

• α1-Adrenergic Agonism: Provides potent vasoconstriction, which reverses the peripheral vasodilation, thereby combating profound hypotension and shock. It also decreases vascular permeability, reducing the formation of angioedema and the loss of fluid from the intravascular space.[7]
• β1-Adrenergic Agonism: Increases the rate and force of cardiac contraction, which helps to maintain cardiac output in the face of falling blood pressure.[14]
• β2-Adrenergic Agonism: Induces powerful relaxation of bronchial smooth muscle, leading to bronchodilation that relieves the life-threatening airway obstruction and wheezing.[7]
• Mast Cell Stabilization: Epinephrine also helps to inhibit the further release of histamine and other inflammatory mediators from mast cells, helping to halt the progression of the reaction.[25]

Because of this unique, multi-pronged action, epinephrine is the first and most critical treatment for anaphylaxis, and any delay in its administration is associated with increased morbidity and mortality.[30]

5.2 The Role in Cardiac Arrest and Resuscitation

Epinephrine has been a central component of Advanced Cardiac Life Support (ACLS) and Pediatric Advanced Life Support (PALS) protocols for decades.[4]

• Mechanism in CPR: During cardiac arrest, the heart is not pumping effectively, and the primary goal of pharmacotherapy is to improve perfusion to vital organs, especially the heart and brain, during chest compressions. The principal benefit of epinephrine in this setting is derived from its potent α1-adrenergic effects.[13] The intense vasoconstriction increases aortic diastolic pressure, which is the driving force for coronary perfusion pressure (CPP). An adequate CPP is essential for achieving the return of spontaneous circulation (ROSC).[13] It also increases cerebral perfusion pressure. The β-adrenergic effects of epinephrine are more controversial in this context; the increased heart rate and contractility significantly increase myocardial oxygen demand, which could potentially worsen ischemia in a heart that is already starved of oxygen.[13]
• The Efficacy Debate: The role of epinephrine in cardiac arrest is a subject of intense debate and ongoing research in modern resuscitation science. While numerous studies have consistently shown that epinephrine administration increases the rate of short-term survival, specifically ROSC, its effect on long-term outcomes is far less clear.[13] Several large, randomized controlled trials have failed to demonstrate a significant improvement in survival to hospital discharge with good neurological function.[14] Some data even suggest that while more patients may survive to hospital admission, they may do so with severe neurological impairment. This has led to a critical re-evaluation of the optimal dose, timing, and overall utility of epinephrine in cardiac arrest, with the understanding that restoring a pulse without restoring a neurologically intact person may not be a desirable outcome.[14]

5.3 Vasopressor Support in Septic Shock

Epinephrine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypotension associated with septic shock.[4] Septic shock is characterized by profound vasodilation and maldistribution of blood flow, leading to life-threatening hypotension and tissue hypoperfusion. Epinephrine, administered as a continuous intravenous infusion, acts as a potent vasopressor. Its α1-agonist effects cause vasoconstriction, increasing systemic vascular resistance and raising the mean arterial pressure (MAP) to a level sufficient to restore perfusion to vital organs.[4] It also provides β1-mediated inotropic support, which can be beneficial in patients with septic cardiomyopathy.[4]

5.4 Emergency Management of Severe Asthma

While inhaled selective β2-agonists (like albuterol) are the first-line treatment for acute asthma exacerbations, epinephrine holds a critical place as a rescue medication in specific emergency scenarios.[43] It is not intended for routine use but is reserved for:

• Life-threatening asthma attacks that are unresponsive to standard inhaled therapies.[4]
• Asthma attacks associated with anaphylaxis or angioedema.[44]
• Emergencies in pre-hospital or remote settings where access to nebulizers or other advanced care is not available.[44]

In these situations, its powerful β2-agonist effect provides potent and rapid bronchodilation, helping to open constricted airways.[2] It can be administered via intramuscular injection or, in a hospital setting, as an intravenous infusion for the most severe, refractory cases of status asthmaticus.[45]

5.5 Adjunct to Local Anesthesia

The co-administration of epinephrine with local anesthetics (e.g., lidocaine, articaine, bupivacaine) is a ubiquitous practice in dentistry and minor surgical procedures.[6] Its inclusion, typically in concentrations of 1:50,000, 1:100,000, or 1:200,000, offers two significant advantages:

1. Prolonged Duration of Anesthesia: By causing local α1-mediated vasoconstriction at the site of injection, epinephrine slows the rate at which the anesthetic is absorbed into the systemic circulation. This "traps" the anesthetic at the nerve, prolonging the duration and increasing the depth of the nerve block, while also reducing the risk of systemic toxicity.[24]
2. Local Hemostasis: The same vasoconstrictive effect reduces local blood flow, providing a clear, bloodless field for the surgical procedure.[48]

A long-standing medical dogma has prohibited the use of epinephrine in areas with end-arterial circulation, such as the fingers, toes, nose, and penis, due to a fear of inducing ischemic necrosis.[49] This belief originated from case reports from the early 20th century, which often involved older, more acidic anesthetic agents like procaine, where the cause of tissue damage was likely misattributed to epinephrine.[52] This dogma represents a classic case of medical tradition being overturned by modern evidence. Numerous clinical studies in recent decades have systematically demonstrated that the injection of modern, pH-neutral local anesthetics like lidocaine with standard concentrations of epinephrine is safe and effective for digital nerve blocks.[52] This evidence-based shift in practice has been transformative, particularly in hand surgery, allowing for procedures to be performed under local anesthesia without the need for a pneumatic tourniquet, which carries its own risks and discomforts.

5.6 Ophthalmic and Ancillary Indications

Epinephrine has several other niche applications:

• Ophthalmology: As a topical ophthalmic solution (e.g., Epifrin, Glaucon), it is used to treat open-angle glaucoma. It is thought to work by both decreasing aqueous humor production (via α-agonism) and increasing its outflow (via β-agonism), thereby lowering intraocular pressure.[6] It is also used as a dilute intraocular solution during surgery to induce and maintain mydriasis (pupil dilation).[4]
• Topical Decongestant: Its vasoconstrictive properties are utilized in some over-the-counter topical preparations for the temporary relief of nasal congestion.[6]

Section 6: Formulations, Dosage, and Administration

The safe and effective use of epinephrine is critically dependent on selecting the correct formulation, concentration, dose, and route of administration for the specific clinical scenario. Medication errors involving epinephrine can be catastrophic, making a thorough understanding of these parameters essential for all healthcare providers.

6.1 Pharmaceutical Preparations

Epinephrine is available in a variety of forms designed for different settings, from community first aid to intensive care.

• Auto-Injectors: These prefilled devices are designed for immediate self-administration or administration by a layperson in the community for the treatment of anaphylaxis. They deliver a single, fixed dose of epinephrine via intramuscular injection. Common brands include EpiPen®, Auvi-Q®, and Symjepi®.[6] Standard strengths are:
• 0.3 mg: For adults and children weighing 30 kg (66 lbs) or more.[32]
• 0.15 mg (e.g., EpiPen Jr®): For children weighing between 15 kg and 30 kg (33-66 lbs).[42]
• 0.1 mg (Auvi-Q® only): For infants and toddlers weighing between 7.5 kg and 15 kg (16.5-33 lbs).[42]
• Vials and Ampules: For use by trained medical professionals, epinephrine is supplied in glass vials or ampules in two primary concentrations. It is critical to note that to reduce medication errors, the historical ratio expressions (e.g., 1:1,000) are being phased out on drug labels in favor of concentration in mg/mL.[42]
• 1 mg/mL (formerly 1:1,000): This is the concentrated solution. It is used for intramuscular or subcutaneous injection for anaphylaxis and severe asthma, and it MUST be diluted before any intravenous use.[32]
• 0.1 mg/mL (formerly 1:10,000): This is the dilute solution, intended primarily for intravenous push administration during cardiac resuscitation.[34]
• Premixed Intravenous Solutions: For continuous IV infusion in the management of shock, epinephrine is available in ready-to-use premixed bags. These solutions contain epinephrine already diluted in a carrier fluid (e.g., 5% Dextrose or 0.9% Sodium Chloride) to standard concentrations such as 8 mcg/mL, 16 mcg/mL, or 32 mcg/mL, enhancing safety by eliminating the need for manual dilution at the bedside.[34]

6.2 Evidence-Based Dosing Regimens and Administration Techniques

The dose of epinephrine varies dramatically depending on the indication, patient weight, and route of administration.

• Anaphylaxis: The standard treatment is intramuscular injection into the mid-anterolateral thigh.
• Adults and Children ≥30 kg: 0.3 to 0.5 mg (0.3 to 0.5 mL of 1 mg/mL solution) IM. The dose may be repeated every 5 to 15 minutes if symptoms persist or worsen.[32]
• Children <30 kg: 0.01 mg/kg (0.01 mL/kg of 1 mg/mL solution) IM, up to a maximum single dose of 0.3 mg. This dose may also be repeated every 5 to 10 minutes as needed.[32]
• Cardiac Arrest (ACLS/PALS Guidelines):
• Adults: 1 mg (10 mL of 0.1 mg/mL solution) IV or IO push, repeated every 3 to 5 minutes for the duration of the resuscitation effort.[29] Each IV dose should be followed immediately by a 20 mL saline flush to ensure the drug reaches the central circulation.[13]
• Pediatrics: 0.01 mg/kg (0.1 mL/kg of 0.1 mg/mL solution) IV or IO push, with a maximum single dose of 1 mg. This is repeated every 3 to 5 minutes.[33]
• Endotracheal Route (if no IV/IO access): The dose is significantly higher due to poor absorption: 2 to 2.5 mg for adults, and 0.1 mg/kg for children (using the 1 mg/mL concentration), diluted in normal saline.[29]
• Hypotension with Septic Shock: Administered as a continuous IV infusion, typically starting at a rate of 0.05 to 2 mcg/kg/minute. The infusion rate is then carefully titrated up or down based on the patient's hemodynamic response, with the goal of achieving a target Mean Arterial Pressure (MAP), usually >65 mmHg.[29]
• Administration Techniques: Proper technique is vital for safety and efficacy.
• IM Injection: The anterolateral thigh is the preferred site. For children, the leg should be held firmly to prevent movement and potential injury (e.g., lacerations, bent or embedded needles).[32]
• Sites to Avoid: Epinephrine should NEVER be injected into the buttocks due to the risk of ineffective absorption and serious clostridial infections (gas gangrene).[51] It should also not be injected into digits, hands, or feet due to the risk of severe vasoconstriction and tissue necrosis.[40]

Table 3: Dosing and Administration Guidelines for Major Indications (Adult & Pediatric)

Indication	Patient Population	Route	Concentration	Dose	Frequency/Notes	Source(s)
Anaphylaxis	Adult / Child ≥30 kg	IM	1 mg/mL	0.3 - 0.5 mg	Repeat every 5-15 min as needed. Use anterolateral thigh.	32
	Child <30 kg	IM	1 mg/mL	0.01 mg/kg (max 0.3 mg)	Repeat every 5-15 min as needed. Use anterolateral thigh.	32
Cardiac Arrest	Adult	IV / IO	0.1 mg/mL	1 mg	Repeat every 3-5 min. Follow IV push with 20 mL saline flush.	13
	Pediatric	IV / IO	0.1 mg/mL	0.01 mg/kg (max 1 mg)	Repeat every 3-5 min.	33
Hypotension with Septic Shock	Adult	IV Infusion	Varies (e.g., 16 mcg/mL)	0.05 - 2 mcg/kg/min	Continuous infusion. Titrate to target Mean Arterial Pressure (MAP).	4
Symptomatic Bradycardia (unresponsive to atropine)	Adult	IV Infusion	Varies	2 - 10 mcg/min	Continuous infusion. Titrate to patient response.	29
Severe Asthma	Adult / Child ≥30 kg	IM / SC	1 mg/mL	0.3 - 0.5 mg	Reserved for severe cases unresponsive to standard therapy.	34

Section 7: Comprehensive Safety Profile and Risk Management

While epinephrine is a life-saving medication, its potency means it carries significant risks if used improperly or in susceptible individuals. Its adverse effects are largely predictable extensions of its powerful sympathomimetic pharmacology. A thorough understanding of its safety profile, contraindications, and drug interactions is crucial for its safe use.

7.1 Adverse Drug Reactions (ADRs)

Adverse reactions to epinephrine can be categorized by their severity and cause.

• Common and Physiologically Predictable ADRs: These effects are common, especially at therapeutic doses, and stem directly from stimulation of the sympathetic nervous system. They include anxiety, fear, restlessness, tremor, palpitations, throbbing headache, dizziness, weakness, pallor, and excessive sweating.[4] While often transient and minor, they can be distressing to the patient.
• Serious Cardiovascular ADRs: These are the most significant risks associated with epinephrine use, particularly with high doses, rapid intravenous administration, or in patients with underlying cardiovascular disease. They include:
• Severe Hypertension: A sharp rise in blood pressure can precipitate a hypertensive crisis, potentially leading to aortic rupture or cerebral hemorrhage, especially in elderly patients.[41]
• Cardiac Arrhythmias: Epinephrine's powerful β1-agonist effects can induce a range of tachyarrhythmias, from sinus tachycardia to supraventricular tachycardia and potentially fatal ventricular arrhythmias, including ventricular fibrillation.[41]
• Myocardial Ischemia and Infarction: By increasing heart rate, contractility, and blood pressure, epinephrine significantly increases myocardial oxygen demand. In patients with pre-existing coronary artery disease, this can precipitate or aggravate angina pectoris and lead to myocardial infarction.[41]
• Administration-Related ADRs:
• Tissue Necrosis: Inadvertent extravasation (leakage) of an intravenous infusion of epinephrine into surrounding tissues can cause intense local vasoconstriction, leading to ischemia and tissue necrosis.[41]
• Injection Site Infections: Although rare, serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the site of intramuscular injections, particularly when administered into the buttock.[55]
• Metabolic ADRs: Epinephrine can cause transient hyperglycemia due to its effects on glycogenolysis, which is a particular concern for patients with diabetes mellitus.[41] It can also cause hypokalemia (due to a shift of potassium into cells) and lactic acidosis, especially with high-dose infusions.[41]

7.2 Contraindications, Warnings, and Precautions

The context of administration (i.e., life-threatening emergency vs. elective procedure) is paramount when considering contraindications.

• Contraindications: In a true life-threatening emergency such as anaphylaxis, there are no absolute contraindications to the use of epinephrine.[32] The risk of withholding treatment far outweighs any potential risk of administration. For non-emergency uses, specific contraindications exist. It should not be used in patients with narrow-angle (or angle-closure) glaucoma, as it can precipitate an acute attack.[51] It is also contraindicated for use with certain halogenated hydrocarbon general anesthetics (e.g., halothane, cyclopropane) that sensitize the myocardium to its arrhythmogenic effects.[51] It should not be used to treat non-anaphylactic shock (e.g., cardiogenic or hemorrhagic shock) as the primary agent.[51]
• Warnings and Precautions: Extreme caution must be exercised when administering epinephrine to patients with certain underlying conditions, as they are at higher risk for adverse events. These conditions include:
• Cardiovascular Disease: Patients with coronary artery disease, cardiac arrhythmias, or hypertension are highly susceptible to the adverse cardiac effects of epinephrine.[51]
• Hyperthyroidism: These patients are often hypersensitive to the effects of catecholamines and may experience an exaggerated response.[51]
• Diabetes Mellitus: Patients may experience significant transient increases in blood glucose.[41]
• Parkinson's Disease: Patients may experience a temporary worsening of symptoms, such as tremor and rigidity.[41]
• Elderly Patients and Pregnant Women: These populations may be at greater risk of developing adverse reactions and should be treated with caution.[39]
• Sulfite Sensitivity: Many epinephrine formulations contain sodium metabisulfite as a preservative, which can cause allergic-type reactions in susceptible individuals. However, the presence of sulfites should not deter the use of epinephrine in a life-threatening emergency.[41]

7.3 Clinically Significant Drug Interactions

Epinephrine's effects can be dangerously altered by a number of other medications. These interactions are a critical risk management consideration.

• Drugs that Potentiate Epinephrine's Effects:
• Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): These drugs block the neuronal reuptake and/or metabolism of catecholamines. Co-administration can lead to a dramatic and dangerous potentiation of epinephrine's cardiovascular effects, resulting in hypertensive crisis and severe arrhythmias.[56]
• COMT Inhibitors (e.g., entacapone): By blocking one of the primary metabolic pathways for epinephrine, these drugs can increase its duration and intensity.[56]
• Levothyroxine and certain Antihistamines (e.g., diphenhydramine, chlorpheniramine): These drugs can sensitize the heart to the effects of epinephrine, increasing the risk of cardiac side effects.[40]
• Drugs that Antagonize Epinephrine's Effects:
• β-Adrenergic Blockers (e.g., propranolol): These drugs directly oppose the β-mediated effects of epinephrine. In a patient on a non-selective β-blocker, administration of epinephrine can lead to unopposed α1-stimulation, resulting in a paradoxical and severe hypertensive crisis. Furthermore, they will block the life-saving β2-mediated bronchodilation needed during anaphylaxis.[55]
• α-Adrenergic Blockers (e.g., phentolamine): These drugs antagonize the α1-mediated vasoconstrictive effects of epinephrine, which can lead to a reversal of its pressor effect and cause hypotension.[4]
• Drugs that Increase the Risk of Arrhythmias:
• Digitalis Glycosides (e.g., digoxin) and Diuretics: Diuretics can cause hypokalemia, which, along with digoxin, sensitizes the myocardium to the arrhythmogenic actions of sympathomimetic drugs like epinephrine.[51]
• Halogenated Anesthetics: As mentioned, agents like halothane dramatically increase the risk of ventricular arrhythmias when used with epinephrine.[51]

Table 4: Clinically Significant Drug Interactions with Epinephrine

Interacting Drug/Class	Example(s)	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
Potentiate Effects
MAO Inhibitors	Phenelzine, Tranylcypromine	Inhibition of MAO, a key metabolic enzyme for epinephrine.	Hypertensive crisis, severe tachycardia.	Combination is generally contraindicated. Use extreme caution and reduced doses if unavoidable.	56
Tricyclic Antidepressants	Amitriptyline, Nortriptyline	Inhibition of norepinephrine/epinephrine reuptake into nerve terminals.	Potentiated pressor effects, hypertension, arrhythmias.	Use with extreme caution. Monitor blood pressure and cardiac rhythm closely.	55
Antagonize Effects
Non-selective β-Blockers	Propranolol, Nadolol	Blockade of β1 and β2 receptors.	Unopposed α1-stimulation leading to severe hypertension; blockade of bronchodilation.	Life-threatening interaction, especially during anaphylaxis. Avoid if possible. Be prepared for blunted response and severe hypertension.	59
α-Blockers	Phentolamine, Prazosin	Blockade of α1 receptors.	Antagonism of vasoconstriction, leading to hypotension ("epinephrine reversal").	Avoid combination. Phentolamine is used as an antidote for epinephrine extravasation.	4
Increase Arrhythmia Risk
Cardiac Glycosides	Digoxin	Increased myocardial sensitivity to catecholamines.	Increased risk of ventricular arrhythmias.	Use with extreme caution. Continuous cardiac monitoring is essential.	51
Diuretics (Potassium-depleting)	Furosemide, Hydrochlorothiazide	Induction of hypokalemia, which sensitizes the myocardium.	Increased risk of arrhythmias.	Monitor potassium levels and cardiac rhythm. Correct hypokalemia before use if possible.	55
Halogenated Anesthetics	Halothane, Isoflurane	Sensitization of the myocardium to arrhythmogenic effects of catecholamines.	Severe ventricular arrhythmias.	Combination is contraindicated or requires extreme caution and specialist anesthetic management.	51

Section 8: Conclusion and Future Perspectives

Epinephrine is a molecule of remarkable significance. From its discovery at the dawn of the 20th century, which helped to define the very concept of a hormone, to its current status as an indispensable tool in emergency medicine, its impact is profound. This report has synthesized the vast body of knowledge surrounding this catecholamine, detailing its history, physicochemical nature, complex pharmacology, diverse clinical applications, and robust safety considerations. The analysis confirms that epinephrine is a powerful, versatile, and fast-acting medication whose safe and effective use is entirely predicated on a sophisticated understanding of its dose-dependent pharmacology and the specific pathophysiology of the condition being treated.

The legacy of epinephrine is not static; it continues to evolve as medical science advances. Several key areas of controversy and future research are poised to refine its role in medicine.

• Optimizing Resuscitation: The most pressing controversy surrounds its use in cardiac arrest. While it reliably improves the return of spontaneous circulation, its failure to consistently improve long-term survival with good neurological outcomes presents a major clinical dilemma. Future research must focus on high-quality trials designed to answer critical questions about optimal dosing strategies (standard vs. high dose), the timing of administration (early vs. late), and whether alternative vasopressors or combination therapies could yield superior results, particularly regarding brain preservation.[13]
• Innovations in Drug Delivery: A major frontier in anaphylaxis management is the development of novel, non-invasive delivery systems. The recognition that needle phobia and user hesitation are significant barriers to the timely administration of life-saving auto-injectors has spurred innovation in this area. The development and clinical validation of formulations such as intranasal sprays (e.g., neffy) hold the promise of improving real-world efficacy by providing a less intimidating, more user-friendly alternative. These technologies could fundamentally change how anaphylaxis is managed in community and school settings.[25]
• Exploring New Biological Roles: The classical view of epinephrine as a systemic stress hormone is being expanded by discoveries of its local production and function. The finding that immune cells can synthesize their own epinephrine suggests a previously unrecognized role in the local microenvironment of inflammation and autoimmunity. Future research in this area could uncover new mechanisms by which epinephrine influences diseases like multiple sclerosis or rheumatoid arthritis and may even lead to novel therapeutic strategies targeting these local catecholamine systems.[22]

In conclusion, epinephrine stands as a pillar of pharmacology and medicine. Its history is a lesson in scientific discovery, its mechanism a model of receptor theory, and its clinical use a daily testament to the power of applied physiology. As research continues to challenge long-held dogma and uncover new biological functions, the story of this century-old molecule is far from over. Its continued relevance is assured, cementing its legacy as one of the most important and enduring drugs in the medical armamentarium.

Works cited

1. en.wikipedia.org, accessed July 21, 2025, https://en.wikipedia.org/wiki/Adrenaline
2. Epinephrine (Adrenaline): What It Is, Function, Deficiency & Side Effects - Cleveland Clinic, accessed July 21, 2025, https://my.clevelandclinic.org/health/articles/22611-epinephrine-adrenaline
3. Physiology, Catecholamines - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507716/
4. Epinephrine - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK482160/
5. Epinephrine - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/29489283/
6. Epinephrine - brand name list from Drugs.com, accessed July 21, 2025, https://www.drugs.com/ingredient/epinephrine.html
7. Epinephrine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00668
8. www.ncbi.nlm.nih.gov, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK482160/#:~:text=Epinephrine%20exerts%20its%20effects%20through,vasoconstriction%20and%20increase%20vascular%20tone.
9. Adrenaline/Epinephrine Hunters: Past, Present, and Future at 1900, accessed July 21, 2025, https://www.gavinpublishers.com/article/view/adrenaline-epinephrine-hunters-past-present-and-future-at-1900
10. Epinephrine Administered in Anaphylaxis: The Evolution of 0.3 mg ..., accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10052460/
11. en.wikipedia.org, accessed July 21, 2025, https://en.wikipedia.org/wiki/Adrenaline#:~:text=In%201897%2C%20John%20Jacob%20Abel,17H15NO4.
12. (−)-Epinephrine | CAS 51-43-4 | SCBT - Santa Cruz Biotechnology, accessed July 21, 2025, https://www.scbt.com/p/epinephrine-51-43-4
13. Part 6: Advanced Cardiovascular Life Support : Section 6 ..., accessed July 21, 2025, https://www.ahajournals.org/doi/10.1161/circ.102.suppl_1.i-129
14. Use of Epinephrine in Cardiac Arrest: Advances and Future Challenges - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11596809/
15. What is the recommended dose of Epinephrine (adrenaline) in cardiac arrest? - Dr.Oracle AI, accessed July 21, 2025, https://www.droracle.ai/articles/30251/epinepherine-dose-in-cardiac-arrest-
16. (–)-Epinephrine (CAS 51-43-4) - Cayman Chemical, accessed July 21, 2025, https://www.caymanchem.com/product/18626/(%E2%80%93)-epinephrine
17. (-)-Epinephrine (Adrenaline), beta2 agonist (CAS 51-43-4) (ab142299) | Abcam, accessed July 21, 2025, https://www.abcam.com/en-us/products/biochemicals/epinephrine-adrenaline-beta2-agonist-ab142299
18. Epinephrine - KEGG DRUG - (www.genome.jp)., accessed July 21, 2025, https://www.genome.jp/dbget-bin/www_bget?D00095
19. Epinephrine | C9H13NO3 - ChemSpider, accessed July 21, 2025, https://www.chemspider.com/Chemical-Structure.5611.html
20. (+)-Epinephrine | C9H13NO3 - ChemSpider, accessed July 21, 2025, https://www.chemspider.com/Chemical-Structure.216840.html
21. www.ncbi.nlm.nih.gov, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507716/#:~:text=Epinephrine%20is%20primarily%20synthesized%20in,to%20produce%20epinephrine%20from%20norepinephrine.
22. Epinephrine Production in Th17 Cells and Experimental Autoimmune Encephalitis - Frontiers, accessed July 21, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.616583/full
23. L(-)-Epinephrine synthesis - chemicalbook, accessed July 21, 2025, https://www.chemicalbook.com/synthesis/l-epinephrine.htm
24. Definition of therapeutic epinephrine - NCI Drug Dictionary, accessed July 21, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/therapeutic-epinephrine
25. What's the mechanism of action for epinephrine? - Drugs.com, accessed July 21, 2025, https://www.drugs.com/medical-answers/mechanism-action-epinephrine-3573625/
26. Epinephrine: A Short- and Long-Term Regulator of Stress and Development of Illness, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11498570/
27. Epinephrine evokes shortening of human airway smooth muscle cells following β2 adrenergic receptor desensitization - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/35787178/
28. Epinephrine Pharmacokinetics - Beginner's Guide – Latrina Walden ..., accessed July 21, 2025, https://shop.latrinawaldenexamsolutions.com/blogs/pmhnp/epinephrine-pharmacokinetics-beginners-guide
29. ACLS and Epinephrine, accessed July 21, 2025, https://acls-algorithms.com/acls-drugs/acls-and-epinephrine/
30. The pharmacokinetics of epinephrine/adrenaline autoinjectors - PMC - PubMed Central, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7938517/
31. www.ncbi.nlm.nih.gov, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK482160/#:~:text=For%20the%20treatment%20of%20anaphylaxis,IV%20or%20IO%20as%20needed.
32. ADRENALIN® (EPINEPHRINE INJECTION, USP) 1mg/mL 1:1000 VIAL - DailyMed, accessed July 21, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7663c49d-1b1d-755d-e053-2991aa0a4ee3&
33. Pediatric Cardiac Arrest Algorithm - American Heart Association CPR and First Aid, accessed July 21, 2025, https://cpr.heart.org/-/media/CPR-Files/CPR-Guidelines-Files/Algorithms/AlgorithmPALS_CA_200707.pdf?sc_lang=en
34. Epinephrine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 21, 2025, https://www.drugs.com/dosage/epinephrine.html
35. Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use - MDPI, accessed July 21, 2025, https://www.mdpi.com/1999-4923/10/1/24
36. Anaphylactic-type reactions Completed Phase Trials for Epinephrine (DB00668) - DrugBank, accessed July 21, 2025, https://go.drugbank.com/indications/DBCOND0102707/clinical_trials/DB00668?phase=&status=completed
37. Upper Respiratory Tract Infection Completed Phase 1 Trials for Epinephrine (DB00668), accessed July 21, 2025, https://go.drugbank.com/indications/DBCOND0035535/clinical_trials/DB00668?phase=1&status=completed
38. www.mayoclinic.org, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/epinephrine-injection-route/description/drg-20072429#:~:text=Back%20to%20top-,Description,substances%20or%20triggered%20by%20exercise.
39. Epinephrine (injection route) - Side effects & dosage - Mayo Clinic, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/epinephrine-injection-route/description/drg-20072429
40. Epinephrine Injection: MedlinePlus Drug Information, accessed July 21, 2025, https://medlineplus.gov/druginfo/meds/a603002.html
41. epinephrine injection usp - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205029s010lbl.pdf
42. EpiPen, Auvi-Q (epinephrine) dosing, indications, interactions ..., accessed July 21, 2025, https://reference.medscape.com/drug/epipen-jr-epinephrine-342437
43. What is the recommended dose of Epinephrine (adrenaline) for ..., accessed July 21, 2025, https://www.droracle.ai/articles/35090/epinepherine-dose-for-asthma
44. Can You Use Epinephrine (or an EpiPen) to Treat an Asthma Attack? - Healthline, accessed July 21, 2025, https://www.healthline.com/health/asthma/epinephrine-for-asthma
45. Intravenous Epinephrine in Life-Threatening Asthma - AAFP, accessed July 21, 2025, https://www.aafp.org/pubs/afp/issues/2004/0101/p203a.html
46. Can a person take epinephrine for asthma? - Medical News Today, accessed July 21, 2025, https://www.medicalnewstoday.com/articles/epinephrine-for-asthma
47. Protocol 6 – Severe Asthma - Center for Wilderness Safety, accessed July 21, 2025, https://wildsafe.org/resources/wilderness-protocols/severe-asthma/
48. Cardiovascular Effects of Epinephrine in Hypertensive Dental ... - NCBI, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK11858/
49. Principles of Office Anesthesia: Part I. Infiltrative Anesthesia - AAFP, accessed July 21, 2025, https://www.aafp.org/pubs/afp/issues/2002/0701/p91.html
50. The influence of epinephrine concentration in local anesthetics on pulpal and gingival blood flows - KoreaMed Synapse, accessed July 21, 2025, https://synapse.koreamed.org/articles/1056083
51. description, accessed July 21, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=4439
52. Epinephrine in Local Anesthesia in Finger and Hand Surgery: The Case for Wide-awake Anesthesia, accessed July 21, 2025, https://handsurgery.org/multimedia/files/preCourse/AAOS%20the%20case%20for%20epinephrine%20in%20finger%20surgery.pdf
53. DRUG GUIDELINE ADRENALINE (epinephrine) - Intravenous, intramuscular, intraosseous and endotracheal), accessed July 21, 2025, https://www.bhs.org.au/bhsapps/govdoc/gdhtml/GDDRG0003-25987-63381.pdf
54. Adult Cardiac Arrest Algorithm - American Heart Association CPR and First Aid, accessed July 21, 2025, https://cpr.heart.org/-/media/CPR-Files/CPR-Guidelines-Files/Algorithms/AlgorithmACLS_CA_200402.pdf?sc_lang=en
55. epinephrine injection - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020800s052lbl.pdf
56. epinephrine injection usp - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205029s006lbl.pdf
57. Epinephrine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 21, 2025, https://www.rxlist.com/epinephrine/generic-drug.htm
58. Epinephrine (Adrenalin): Uses, Side Effects, Alternatives & More - GoodRx, accessed July 21, 2025, https://www.goodrx.com/epinephrine-adrenalin/what-is
59. FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Epinephrine Injection, 0.3 mg and Epinephrine Injection, 0.15 mg are indic - Teva-epinephrine, accessed July 21, 2025, https://www.tevaepinephrine.com/modules/Teva.Epinephrine/Client/Static%20Files/Epinephrine%20Auto-Injector_PI.pdf
60. EpiPen interactions: Alcohol, medications, and other factors, accessed July 21, 2025, https://www.medicalnewstoday.com/articles/drugs-epipen-interactions
61. Epinephrine Interactions Checker - Drugs.com, accessed July 21, 2025, https://www.drugs.com/drug-interactions/epinephrine.html